UHeart, UKidney, and UThymoKidney — Milestone payment to be made
United Therapeutics UHeart, UKidney, and UThymoKidney — Milestone payment to be made remained flat by 0.0% to $6.25M in Q4 2025 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from $6.25M to $6.25M. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
An increase suggests a growing pipeline of committed development costs, while a decrease indicates the completion of milestone obligations or a reduction in the scope of the program.
Detailed definition
This represents the total outstanding contractual obligations for future milestone payments related to the development o...
Peer comparison
Similar to contingent consideration or milestone obligations found in biotech licensing agreements, often disclosed in the notes to financial statements.
uthr_segment_uheart_ukidney_and_uthymokidney_milestone_payment_to_be_madeHistorical Data
| FY'24 | FY'25 | |
|---|---|---|
| Value | $25.00M | $25.00M |
| YoY Change | — | +0.0% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is United Therapeutics's uheart, ukidney, and uthymokidney — milestone payment to be made?
- United Therapeutics (UTHR) reported uheart, ukidney, and uthymokidney — milestone payment to be made of $6.25M in Q4 2025.
- How has United Therapeutics's uheart, ukidney, and uthymokidney — milestone payment to be made changed year-over-year?
- United Therapeutics's uheart, ukidney, and uthymokidney — milestone payment to be made decreased by 0.0% year-over-year, from $6.25M to $6.25M.
- What does uheart, ukidney, and uthymokidney — milestone payment to be made mean?
- The total amount of future payments the company is contractually obligated to pay upon reaching specific development or commercial goals for these programs.